Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF
US ˙ BATS

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mohammad Azab. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mohammad Azab has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:LSTA / Lisata Therapeutics, Inc. Director 74,469
US:XENE / Xenon Pharmaceuticals Inc. Director 74,225
US:DRRX / DURECT Corporation Director 60,000
US:ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF Chief Medical Officer 0
US:QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF Exec VP-R&D, CMO 200
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mohammad Azab. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF Insider Trades
Insider Sales ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF Insider Trades
Insider Purchases DRRX / DURECT Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-05-24 DRRX AZAB MOHAMMAD 5,000 0.3925 500 3.9250 1,962 83 9.1 2,588 131.91
2022-05-24 DRRX AZAB MOHAMMAD 5,000 0.3884 500 3.8840 1,942
2022-05-24 DRRX AZAB MOHAMMAD 5,000 0.3789 500 3.7890 1,894
2022-05-24 DRRX AZAB MOHAMMAD 10,000 0.3889 1,000 3.8890 3,889
2022-05-24 DRRX AZAB MOHAMMAD 5,000 0.3900 500 3.9000 1,950
2022-05-17 DRRX AZAB MOHAMMAD 9,300 0.4193 930 4.1930 3,899
2022-05-17 DRRX AZAB MOHAMMAD 8,900 0.4212 890 4.2120 3,749
2022-05-17 DRRX AZAB MOHAMMAD 1,800 0.4213 180 4.2130 758
2022-05-16 DRRX AZAB MOHAMMAD 10,000 0.3767 1,000 3.7670 3,767

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DRRX / DURECT Corporation Insider Trades
Insider Sales DRRX / DURECT Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DRRX / DURECT Corporation Insider Trades
Insider Purchases LSTA / Lisata Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Sales LSTA / Lisata Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Purchases QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF Insider Trades
Insider Sales QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF Insider Trades
Insider Purchases XENE / Xenon Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-11-15 XENE AZAB MOHAMMAD 15,000 2.2187 15,000 2.2187 33,280 300 14.9 190,220 571.57
2017-09-22 XENE AZAB MOHAMMAD 8,000 2.9500 8,000 2.9500 23,600
2017-09-21 XENE AZAB MOHAMMAD 2,000 2.9500 2,000 2.9500 5,900
2017-08-18 XENE AZAB MOHAMMAD 6,312 2.8995 6,312 2.8995 18,302
2017-08-17 XENE AZAB MOHAMMAD 23 2.6500 23 2.6500 61

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XENE / Xenon Pharmaceuticals Inc. Insider Trades
Insider Sales XENE / Xenon Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2019-09-13 XENE AZAB MOHAMMAD 23 9.3122 23 9.3122 214 187 8.08 -28 -13.16

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XENE / Xenon Pharmaceuticals Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mohammad Azab as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-13 2025-01-09 4 LSTA LISATA THERAPEUTICS, INC.
Common Stock
A - Award 15,789 74,469 26.91
2024-01-11 2024-01-09 4 LSTA LISATA THERAPEUTICS, INC.
Common Stock
A - Award 19,480 58,680 49.69
2023-12-20 2023-12-19 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 3,497 74,225 4.94 9.85 34,445 731,116
2023-12-20 2023-12-19 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 823 70,728 1.18 9.85 8,107 696,671
2023-01-11 2023-01-09 4 LSTA LISATA THERAPEUTICS, INC.
Common Stock
A - Award 20,000 39,200 104.17
2022-12-13 2022-12-12 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 3,086 69,905 4.62 2.68 8,270 187,345
2022-09-16 2022-09-15 4 LSTA LISATA THERAPEUTICS, INC.
Common Stock
A - Award 19,200 19,200 6.25 120,000 120,000
2022-05-25 2022-05-24 4 DRRX DURECT CORP
Common Stock
P - Purchase 5,000 60,000 9.09 0.39 1,950 23,400
2022-05-25 2022-05-24 4 DRRX DURECT CORP
Common Stock
P - Purchase 10,000 55,000 22.22 0.39 3,889 21,390
2022-05-25 2022-05-24 4 DRRX DURECT CORP
Common Stock
P - Purchase 5,000 45,000 12.50 0.38 1,894 17,050
2022-05-25 2022-05-24 4 DRRX DURECT CORP
Common Stock
P - Purchase 5,000 40,000 14.29 0.39 1,942 15,536
2022-05-25 2022-05-24 4 DRRX DURECT CORP
Common Stock
P - Purchase 5,000 35,000 16.67 0.39 1,962 13,738
2022-05-18 2022-05-17 4 DRRX DURECT CORP
Common Stock
P - Purchase 1,800 30,000 6.38 0.42 758 12,639
2022-05-18 2022-05-17 4 DRRX DURECT CORP
Common Stock
P - Purchase 8,900 28,200 46.11 0.42 3,749 11,878
2022-05-18 2022-05-17 4 DRRX DURECT CORP
Common Stock
P - Purchase 9,300 19,300 93.00 0.42 3,899 8,092
2022-05-18 2022-05-16 4 DRRX DURECT CORP
Common Stock
P - Purchase 10,000 10,000 0.38 3,767 3,767
2021-12-17 2021-12-15 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -3,086 0 -100.00
2021-12-17 2021-12-15 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 3,086 66,819 4.84 3.67 11,326 245,226
2021-06-16 2021-06-15 4 DRRX DURECT CORP
Stock Option (right to buy)
A - Award 27,500 27,500
2021-06-03 2021-06-03 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2021-01-05 2021-01-04 4 DRRX DURECT CORP
Stock Option (right to buy)
A - Award 70,000 70,000
2020-12-15 2020-12-15 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -3,086 0 -100.00
2020-12-15 2020-12-15 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 3,086 63,733 5.09 3.76 11,603 239,636
2020-06-02 2020-06-01 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2019-12-17 2019-12-16 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -3,086 0 -100.00
2019-12-17 2019-12-16 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 3,086 60,647 5.36 3.56 10,986 215,903
2019-09-17 2019-09-16 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2019-09-17 2019-09-13 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
S - Sale -23 57,561 -0.04 9.31 -214 536,020
2018-12-10 2018-12-06 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -3,086 0 -100.00
2018-12-10 2018-12-06 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 3,086 57,584 5.66 3.07 9,474 176,783
2018-06-22 2018-06-21 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -10,288 0 -100.00
2018-06-22 2018-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 10,288 54,498 23.27 3.70 38,066 201,643
2018-06-05 2018-06-04 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2017-11-16 2017-11-15 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
P - Purchase 15,000 44,210 51.35 2.22 33,280 98,089
2017-09-25 2017-09-22 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
P - Purchase 8,000 29,210 37.72 2.95 23,600 86,170
2017-09-25 2017-09-21 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
P - Purchase 2,000 21,210 10.41 2.95 5,900 62,570
2017-08-21 2017-08-18 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
P - Purchase 6,312 19,210 48.94 2.90 18,302 55,699
2017-08-21 2017-08-17 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
P - Purchase 23 12,898 0.18 2.65 61 34,180
2017-06-02 2017-06-01 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 3,500 3,500
2016-12-02 2016-12-01 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -12,345 0 -100.00
2016-12-02 2016-12-01 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
F - Taxes -4,408 12,875 -25.50 7.80 -34,382 100,425
2016-12-02 2016-12-01 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 12,345 17,283 250.00 3.21 39,627 55,478
2016-06-03 2016-06-02 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 3,500 3,500
2015-12-14 2015-12-11 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise 2,469 0 -100.00
2015-12-14 2015-12-11 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 2,469 4,938 100.00 5.22 12,888 25,776
2015-05-06 2015-05-04 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 3,086 3,086
2015-01-12 2015-01-08 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -2,469 0 -100.00
2015-01-12 2015-01-08 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 2,469 2,469 4.98 12,296 12,296
2014-11-06 2014-11-04 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 5,144 5,144
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -300,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -200,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -280,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -60,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -260,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
U - Other -8,753 0 -100.00
2012-12-10 2012-12-06 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
A - Award 300,000 300,000
2012-03-09 2012-03-07 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
A - Award 200,000 200,000
2004-11-29 3 QLTI QLT INC/BC
Common Stock
200
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)